Framework Agreement for the Purchase of Breyanzi (lisocabtagene maraleucel)

This framework agreement aims to supply hospital pharmacies within Amgros' stakeholder network with the medicinal product Breyanzi (lisocabtagene maraleucel). The Central Denmark Region's hospital pharmacy will also procure this medication for resale to Greenland and the Faroe Islands. Breyanzi is a CAR T-cell therapy, a type of immunotherapy used in the treatment of certain types of cancer, specifically certain B-cell lymphomas. The agreement will establish the terms and conditions under which Amgros, acting on behalf of its stakeholders, can procure this advanced therapy. Key aspects of the agreement will likely include supply chain management, pricing, quality assurance, and delivery protocols to ensure consistent availability for patient treatment. The inclusion of Greenland and the Faroe Islands in the resale arrangement highlights the broad geographical scope of this procurement. This initiative underscores Amgros' commitment to providing access to innovative and critical medical treatments for patients across its service regions, ensuring that healthcare providers have the necessary resources to manage complex oncological conditions. The framework agreement is expected to facilitate efficient and cost-effective procurement of this specialized pharmaceutical product.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Denmark, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.